Hepatocelulárny karcinóm na strednom Slovensku – analýza kohorty 207 pacientov v nemocnici 3. stupňa

Úvod:
Vlastnosti hepatocelulárneho karcinómu (HCC) z rôznych geografických oblastí sú odlišné.

Cieľ:
Analyzovať kohortu pacientov v nemocnici 3. stupňa.

Metodológia:
Retrospektívna analýza za sebou idúcich pacientov. Vstupné kritériá: HCC; vylučovacie kritériá: nedostatok dát; interval: roky 2007–2016.

Výsledky:
Súbor 207 pacientov, 95 % s cirhózou, 76 % mužov; vek 62 rokov. Etiológia hepatálneho ochorenia: Alkohol (ALD) 106 (48 %), hepatitída C 17 %, hepatitída B 13 %, nealkoholová steatohepatitída 10 %, kryptogénna 7 %, necirhotická 4 %, iná 1 %. Diagnóza prostredníctvom surveillance 24 %, bez surveillance 67 %, neznámy spôsob diagnózy 9 %. Priemer ložiska pri diagnóze SUR-HCC 5 cm, bez SUR-HCC 8,6 cm (p = 0,001). BCLC štádium: A – 30 pacientov (15 %), B – 29 %, C – 36 %, D – 20 %; BCLC podľa diagnózy (SUR-HCC vs. non-SUR-HCC): A – 15/49 (31 %) vs. 12/140 (9 %), B 43 vs. 27 %, C – 16 vs. 39 %, D – 10 vs. 25 %. Terapia: Chirurgická resekcia 17 pacientov (7 %), transplantácia pečene 14 (6 %), rádiofrekvenčná ablácia 20 (8 %), transarteriálna chemoembolizácia 60 (24 %), sorafenib 88 (35 %), suportívna starostlivosť 46 (19 %), 3 pacienti sú čakateľmi na transplantaci pečene. Priemerné prežívanie 17 (0,06–112) mesiacov, prežívanie podľa BCLC: A – 37 (2–112), B – 21 (0,6–86), C – 14 (0,06–92), D – 3 (0,06–24) mesiacov.

Záver:
Demografické údaje v našej kohorte sú porovnateľné s krajinami západnej Európy a Severnej Ameriky. ALD bola najčastejšou etiológiou základného ochorenia pečene, 95 % pacientov malo cirhózu. Len 24 % pacientov bolo zachytených prostredníctvom SUR-HCC, preto bol zaznamenaný výrazný posun doprava v BCLC štádiách, čo viedlo k suboptimálnej alokácii radikálnej liečby a následne aj k horšiemu prežívaniu. Súhrnne sú tieto výsledky porovnateľné s údajmi z Európy a Severnej Ameriky.

Kľúčové slová:
hepatocelulárny karcinóm – kohorta – diagnóza – liečba – prežívanie – surveillance

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

Doručeno:
23. 10. 2017

Přijato:
25. 11. 2017

Autoři: L. Skladaný ¹; S. Adamcova-Selcanova ¹; V. Malec ²; J. Badinkova ¹; E. Pritzova ²; J. Janek ³; S. Okapec ⁴
Působiště autorů: HEGITO (Division of Hepatology, Gastroenterology and Liver Transplantation), Department of Internal Medicine II, Slovak Medical University, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic ¹; Department of Oncology, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic ²; Department of Surgery, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic ³; Department of Radiology, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic ⁴
Vyšlo v časopise: Gastroent Hepatol 2018; 72(2): 99-107
Kategorie: Hepatologie: původní práce
prolekare.web.journal.doi_sk: https://doi.org/10.14735/amgh201899

Souhrn

Úvod:
Vlastnosti hepatocelulárneho karcinómu (HCC) z rôznych geografických oblastí sú odlišné.

Cieľ:
Analyzovať kohortu pacientov v nemocnici 3. stupňa.

Metodológia:
Retrospektívna analýza za sebou idúcich pacientov. Vstupné kritériá: HCC; vylučovacie kritériá: nedostatok dát; interval: roky 2007–2016.

Doručeno:
23. 10. 2017

Přijato:
25. 11. 2017

Zdroje

1. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012; 380 (9859): 2095–2128. doi: 10.1016/S0140-6736 (12) 61728-0.

2. Jemal A, Simard EP, Dorell C et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV) -associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105 (3): 175–201. doi: 10.1093/jnci/djs491.

3. Noureddin M, Rinella ME. Nonalcoholic fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis 2015; 19 (2): 361–379. doi: 10.1016/j.cld.2015.01.012.

4. Archambeaud I, Auble H, Nahon P et al. Risk factors for hepatocellular carcinoma in Caucasian patients with non-viral cirrhosis: the importance of prior obesity. Liver Int 2015; 35 (7): 1872–1876. doi: 10.1111/liv.12767.

5. Omata M, Dan Y, Daniele B et al. Clinical features, etiology, and survival of hepatocellular carcinoma among different countries. J Gastroenterol Hepatol 2002; 17 (Suppl): S40–S49.

6. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127 (5 Suppl 1): S5–S16.

7. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5 Suppl 1): S27–S34.

8. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132 (7): 2557–2576.

9. Khan SA, Taylor-Robinson SD, Toledano MB el al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37 (6): 806–813.

10. De Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63 (3): 743–752. doi: 10.1016/j.jhep.2015.05.022.

11. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28 (5): 753–770. doi: 10.1016/j.bpg.2014.08.007.

12. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65 (2): 87–108. doi: 10.3322/caac.21262.

13. Bosch FX, Ribes J, Cléries R et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9 (2): 191–211.

14. World Health Organization, International Agency for Cancer Research. The global burden of disease. 2004 update. Globocan 2008. [online]. Available from: http: //www.who.int/healthinfo/global_burden_disease/GBD_report_2004 update_full.pdf.

15. Frey RS, Boldanova T. Heim MH. Ultrasound surveillance for hepatocellular carcinoma: real-life performance in a hepatology outpatient clinic. Swiss Med Wkly 2015; 145: w14200. doi: 10.4414/smw.2015.14200.

16. Harrison SA, Diehl AM. Fat and the liver: a molecular overview. Semin Gastrointest Dis 2002; 13 (1): 3–16.

17. Festi D, Colecchia A, Sacco T et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5 (1): 27–42.

18. Skladaný Ľ (ed). Infekcia vírusom hepatitídy B a hepatocelulárny karcinóm. Trendy v hepatol 2009; 3: 12–21.

19. Skladaný Ľ, Adamcová-Selčanová S, Badinková J et al. Hepatocelulárny karcinóm. Onkológia VIP 2013: 1–8.

20. Skladaný Ľ, Adamcová-Selčanová S, Pritzová E. Hepatocelulárny karcinóm BCLC-C liečený sorafenibom. Farmakoterapia 2013; 3: 20–25.

21. Adamcová-Selčanová S, Skladaný Ľ, Badinková J. Hepatocelulárny karcinóm a využitie sorafenibu. Farmakoterapie 2013; 3 (2): 78–80.

22. EL-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014; 60 (5): 1767–1775. doi: 10.1002/hep.27222.

23. Njei B, Rotman Y, Ditah I et al. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015; 61 (1): 191–199. doi: 10.1002/hep.27388.

24. Kudo M. Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer 2015; 4 (1): 39–50. doi: 10.1159/000367727.

25. Sawyers CL, Abate-Shen C, Anderson KC et al. AACR cancer progress report 2013. Clin Cancer Res 2013; 19 (20 Suppl): S4–S98. doi: 10.1158/1078-0432.CCR-13-2107.

26. Benvegnù L, Gios M, Boccato S et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53 (5): 744–749.

27. Skladaný Ľ, Adamcová-Selčanová S, Dropčová A et al. Transplantácia pečene. Interná Med 2015; 3: 93–101.

28. Lang K, Danchenko N, Gondek K et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol 2009; 50 (1): 89–99. doi: 10.1016/j.jhep.2008.07.029.

29. Arguedas MR, Chen VK, Eloubeidi MA et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98 (3): 679–690.

30. Armstrong GL, Alter MJ, McQuillan GM et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31 (3): 777–782.

31. Singal A, Volk ML, Waljee A et al. Metaanalysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30 (1): 37–47. doi: 10.1111/j.1365-2036.2009.04014.x.

32. Piscaglia F, Svegliati-Baroni G, Barchetti A et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology 2016; 63 (3): 827–838. doi: 10.1002/hep.28368.

33. Perumpail RB, Wong RJ, Ahmed A et al. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience. Dig Dis Sci 2015; 60 (10): 3142–3148. doi: 10.1007/s10620-015-3821-7.

34. Farinati F, Sergio A, Baldan A et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009; 9: 33. doi: 10.1186/1471-2407-9-33.

35. Wang C, Wang H, Yang W et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61: 1579–1590. doi: 10.1002/hep.27548.

36. Žigrai M, Skladaný Ľ, Hrušovský Š et al. Štandardný diagnostický a terapeutický postup. Manažment liečby hepatocelulárneho karcinómu. Metodický list racionálnej farmakoterapie 2013; 16: 1–8.

37. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35 (3): 421–430.

38. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3): 1020–1022. doi: 10.1002/hep.24199.

39. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56 (4): 908–943. doi: 10.1016/j.jhep.2011.12.001.

40. Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost-effectiveness analysis. Gut 2001; 48 (2): 251–259.

41. Sherman M, Bruix J, Porayko M et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology 2012; 56 (3): 793–796. doi: 10.1002/hep.25869.

42. Altekruse SF, McGlynn KA, Reichman ME et al. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27 (9): 1485–1491. doi: 10.1200/JCO.2008.20.7753.

43. Mittal S, Sada YH, El-Serag HB et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015; 13 (3): 594–601. doi: 10.1016/j.cgh.2014.08. 013.

44. Sangiovanni A, Del Ninno E, Fasani P. Increas-ed survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 2004; 126 (4): 1005–1014.

45. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 1999; 31 (Suppl 1): 25–30.

46. Velázquez RF, Rodríguez M, Navascués CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003; 37 (3): 520–527.

47. Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20 (1): 65–71.

48. Chan EY, Larson AM, Fix OK et al. Identifying risk for recurrent hepatocellular carcinoma after liver transplantation: implications for surveillance studies and new adjuvant therapies. Liver Transpl 2008; 14 (7): 956–965. doi: 10.1002/lt.21449.

49. Yuen MF, Cheng CC, Lauder IJ et al. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31 (2): 330–335.

50. Toyoda H, Kumada T, Osaki Y el al. Staging hepatocellular carcinoma by a novel scoring system (balad score) based on serum markers. Clin Gastroenterol Hepatol 2006; 4 (12): 1528–1536.

51. Mc Mahon BJ, Bulkow L, Harpster A el al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32 (4 Pt 1): 842–846.

52. Yu SJ. A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010–2016. Clin Mol Hepatol 2016; 22 (1): 7–17. doi: 10.3350/cmh.2016.22.1.7.

53. Bialecki ES, Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7 (1): 26–34. doi: 10.1080/13651820410024 049.

54. Bialecki ES, Ezenekwe AM, Brunt EM et al. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4 (3): 361–368.

55. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150 (4): 835–853. doi: 10.1053/j.gastro.2015.12.041.

56. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35 (3): 519–524.

57. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42 (5): 1208–1236.

58. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53 (3): 1020–1022. doi: 10.1002/hep.24199.

59. Forner A, Hessheimer AJ, Isabel Real M et al. Treatment of hepatocellular carcinoma. Crit Rev Oncol Hematol 2006; 60 (2): 89–98.

60. Oliverius M, Bĕlina F, Novotný J et al. Treatment of hepatocellular carcinoma and current situation in the Czech Republic. Rozhl Chir 2007; 86 (12): 635–641.

61. Forner A, Reig ME, De Lope CR et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30 (1): 61–74. doi: 10.1055/s-0030-1247133.

62. Brůha R, Drastich P, Hůlek P et al. Diagnostika a léčba hepatocelulárního karcinomu. Vnitr Lek 2005; 51 (12): 1406–1408.

63. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10 (1): 35–43. doi: 10.1016/S1470-2045 (08) 70284-5.

64. Suchánková G, Špičák J. Sorafenib in the treatment of hepatocellular carcinoma. Vnitr Lek 2011; 57 (5): 485–490.

65. Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7 (4): 673–687. doi: 10.4254/wjh.v7.i4.673.

66. Bruix J, Llovet JM, Castells A et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27 (6): 1578–1583.

67. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734–1739.

68. Marelli L, Stigliano R, Triantos C et al. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006; 32 (8): 594–606.

69. Varela M, Real MI, Burrel M et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efﬁcacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46 (3): 474–481.

70. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24 (26): 4293–4300.

71. Kim Je, Ryoo BY, Ryu MH et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother Pharmacol 2011; 68 (5): 1285–1290. doi: 10.1007/s00280-011-1616-x.

72. Llovet J, Ricci S, Mazzaferro V et al. Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007; 25 (Suppl 18): Abstract LBA1.

73. Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11 (7): 790–800.

74. Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136 (5): E359–E386. doi: 10.1002/ijc.29210.

75. Park JW, Chen M, Colombo M et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015; 35 (9): 2155–2166. doi: 10.1111/liv.12818.

76. Giannini EG, Cucchetti A, Erroi V et al. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19 (47): 8808–8821. doi: 10.3748/wjg.v19.i47.8808.

77. Weinmann A, Koch S, Niederle IM et al.Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. J Clin Gastroenterol 2014; 48 (3): 279–289. doi: 10.1097/MCG.0b013e3182a8a793.

78. Jepsen P, Andersen MW, Villadsen GE et al. Time-trends in incidence and prognosis of hepatocellular carcinoma in Denmark: a nationwide register-based cohort study. Liver Int 2017; 37 (6): 871–878. doi: 10.1111/liv.13340.

79. Eskesen AN, Bjøro K, Aandahl EM et al. Low use of surveillance and early diagnosis of hepatocellular carcinoma in Norway – a population-based cohort study. Cancer Epidemiol 2014; 38 (6): 741–747.

80. Duan XY, Qiao L, Fan JG. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2012; 11 (1): 18–27.

81. Leung CH, Yeoh SW, Patrick D et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21 (4): 1189–1196. doi: 10.3748/wjg.v21.i4.1189.

82. Ng M, Freeman MK, Fleming TD el al. Smoking prevalence and cigarette consumption in 187 countries, 1980–2012. JAMA 2014; 311 (2): 183–192. doi: 10.1001/jama.2013.284692.

83. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387 (10027): 1513–1530. doi: 10.1016/ S0140-6736 (16) 00618-8.

84. Hoşcan Y, Yiğit F, Müderrisoğlu H. Adherence to Mediterranean diet and its relation with cardiovascular diseases in Turkish population. Int J Clin Exp Med 2015; 8 (2): 2860–2866.

85. Turati F, Trichopoulos D, Polesel J et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol 2014; 60 (3): 606–611. doi: 10.1016/j.jhep.2013.10.034.

86. Pisani P, Parkin DM, Muñoz N et al. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997; 6 (6): 387–400.

87. Bucci L, Garuti F, Lenzi B et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int 2017; 37 (2): 259–270. doi: 10.1111/liv.13204.

88. Dyson J, Jaques B, Chattopadyhay D et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014; 60 (1): 110–117. doi: 10.1016/j.jhep.2013.08.011.

89. Szántová M. Alkohol a pečeň pohľadom hepatológa. Psychiatr prax 2013; 14 (3): 114–119.

90. Szántová M. Epidemiologický prehľad spotreby alkoholu v SR a ČR. Prakt Lék 2006; 86 (7): 374–380.

91. Szántová M. Diagnostika a liečba alkoholového poškodenia pečene. Via pract 2008; 5 (4–5): 170–172.

92. Szántová M. Alkoholová choroba pečene vo svetle nových EASL odporúčaní. Intern Med 2012; 12 (9): 433–440.

93. Szántová M. Alkoholová choroba pečene. Alkoholizmus a drogové závislosti (protialkoholický obzor) 2013; 48 (1): 25–35.

94. Rehm J, Shield KD, Rehm M et al. Alcohol consumption, alcohol dependence and attributable burden of disease in Europe: potential gains from eff ective interventions for alcohol dependence. Toronto: CAMH 2012.

95. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289–293.

96. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130 (7): 417–422.

97. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United states of America. J Gastroenterol Hepatol 2001; 16 (5): 553–559.

98. Singal AG, El-Serag HB. Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clin Gastroenterol Hepatol 2015; 13 (12): 2140–2151. doi: 10.1016/j.cgh.2015.08.014.

99. Gomaa AI, Hashim MS, Waked I. Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One 2014; 9 (3): e90929. doi: 10.1371/journal.pone.0090929.

100. Fenoglio L, Serraino C, Castagna E et al. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013; 19 (21): 3207–3216. doi: 10.3748/wjg.v19.i21.3207.

101. El-Serag HB et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006; 44 (1): 158–166.